3-hydroxybutyric acid has been researched along with Parkinson Disease in 11 studies
3-Hydroxybutyric Acid: BUTYRIC ACID substituted in the beta or 3 position. It is one of the ketone bodies produced in the liver.
3-hydroxybutyric acid : A straight-chain 3-hydroxy monocarboxylic acid comprising a butyric acid core with a single hydroxy substituent in the 3- position; a ketone body whose levels are raised during ketosis, used as an energy source by the brain during fasting in humans. Also used to synthesise biodegradable plastics.
Parkinson Disease: A progressive, degenerative neurologic disease characterized by a TREMOR that is maximal at rest, retropulsion (i.e. a tendency to fall backwards), rigidity, stooped posture, slowness of voluntary movements, and a masklike facial expression. Pathologic features include loss of melanin containing neurons in the substantia nigra and other pigmented nuclei of the brainstem. LEWY BODIES are present in the substantia nigra and locus coeruleus but may also be found in a related condition (LEWY BODY DISEASE, DIFFUSE) characterized by dementia in combination with varying degrees of parkinsonism. (Adams et al., Principles of Neurology, 6th ed, p1059, pp1067-75)
| Excerpt | Relevance | Reference |
|---|---|---|
| "It is widely accepted that ketosis (increased blood ketone body levels, e." | 2.72 | Beneficial Effects of Exogenous Ketogenic Supplements on Aging Processes and Age-Related Neurodegenerative Diseases. ( Ari, C; Brunner, B; Kovács, Z, 2021) |
| "Unified Parkinson's Disease Rating Scale scores improved in all five during hyperketonemia, but a placebo effect was not ruled out." | 2.71 | Treatment of Parkinson disease with diet-induced hyperketonemia: a feasibility study. ( Boyar, K; Di Rocco, A; Heymsfield, SB; Hyams, K; Nonas, C; Vanitallie, TB, 2005) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 4 (36.36) | 29.6817 |
| 2010's | 4 (36.36) | 24.3611 |
| 2020's | 3 (27.27) | 2.80 |
| Authors | Studies |
|---|---|
| Jiang, Z | 3 |
| Yin, X | 3 |
| Wang, M | 3 |
| Wang, Y | 3 |
| Li, F | 3 |
| Gao, Y | 3 |
| Han, G | 3 |
| Gao, Z | 3 |
| Wang, Z | 3 |
| Kovács, Z | 1 |
| Brunner, B | 1 |
| Ari, C | 1 |
| Kuter, KZ | 1 |
| Olech, Ł | 1 |
| Głowacka, U | 1 |
| Paleczna, M | 1 |
| Deora, V | 1 |
| Albornoz, EA | 1 |
| Zhu, K | 1 |
| Woodruff, TM | 1 |
| Gordon, R | 1 |
| Paoli, A | 1 |
| Bianco, A | 1 |
| Damiani, E | 1 |
| Bosco, G | 1 |
| Fu, SP | 1 |
| Wang, JF | 1 |
| Xue, WJ | 1 |
| Liu, HM | 1 |
| Liu, BR | 1 |
| Zeng, YL | 1 |
| Li, SN | 1 |
| Huang, BX | 1 |
| Lv, QK | 1 |
| Wang, W | 1 |
| Liu, JX | 1 |
| Kabiraj, P | 1 |
| Pal, R | 1 |
| Varela-Ramirez, A | 1 |
| Miranda, M | 1 |
| Narayan, M | 1 |
| Tieu, K | 1 |
| Perier, C | 2 |
| Caspersen, C | 1 |
| Teismann, P | 1 |
| Wu, DC | 1 |
| Yan, SD | 1 |
| Naini, A | 1 |
| Vila, M | 1 |
| Jackson-Lewis, V | 1 |
| Ramasamy, R | 1 |
| Przedborski, S | 2 |
| Vanitallie, TB | 1 |
| Nonas, C | 1 |
| Di Rocco, A | 1 |
| Boyar, K | 1 |
| Hyams, K | 1 |
| Heymsfield, SB | 1 |
| Ved, R | 1 |
| Saha, S | 1 |
| Westlund, B | 1 |
| Burnam, L | 1 |
| Sluder, A | 1 |
| Hoener, M | 1 |
| Rodrigues, CM | 1 |
| Alfonso, A | 1 |
| Steer, C | 1 |
| Liu, L | 1 |
| Wolozin, B | 1 |
| Kashiwaya, Y | 1 |
| Takeshima, T | 1 |
| Mori, N | 1 |
| Nakashima, K | 1 |
| Clarke, K | 1 |
| Veech, RL | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Keto-diet for Intubated Critical Care COVID-19 (KICC-COVID19)[NCT04358835] | 0 participants (Actual) | Interventional | 2020-09-01 | Withdrawn (stopped due to Study did not begin enrollment, multiple competing studies at same institution) | |||
| Randomized-controlled Study for Evaluation of Ketogenic Metabolic Nutritional Pattern in Subjects With High-frequency Episodic Migraine[NCT04360148] | 58 participants (Anticipated) | Interventional | 2020-02-06 | Active, not recruiting | |||
| Ketogenic Diet Interventions in Parkinson's Disease: Safeguarding the Gut Microbiome[NCT05469997] | 50 participants (Anticipated) | Interventional | 2023-01-31 | Not yet recruiting | |||
| Ketogenic Diet in McArdle Disease: a Multicentric Single Blind Controlled Trial[NCT04292938] | 16 participants (Actual) | Interventional | 2019-03-25 | Completed | |||
| The Safety and Effects on Whole Organism of Low Energy Ketogenic Diet for Weight Loss in Obese Subjects[NCT03338452] | 38 participants (Actual) | Interventional | 2017-03-18 | Completed | |||
| Effect of a Lipidic and Proteic Controlled Diet on Resting Energy Expenditure, Body Composition and Symptoms in Patients With Parkinson's Disease[NCT02687698] | 36 participants (Anticipated) | Interventional | 2016-02-29 | Enrolling by invitation | |||
| A Randomized, Double-blind Multicenter Pilot Study vs. Placebo for the Evaluation of Efficacy and Tolerability of Tauroursodeoxycholic Acid Administered by Oral Route as Add on Treatment in Patients Affected by Amyotrophic Lateral Sclerosis[NCT00877604] | Phase 2 | 34 participants (Actual) | Interventional | 2008-06-30 | Completed | ||
| Safety, Tolerability and Efficacy Study of Tricaprilin (AC-1202) Administered for Ninety Days in Subjects With Probable Alzheimer's Disease of Mild to Moderate Severity[NCT00142805] | Phase 2 | 152 participants (Actual) | Interventional | 2004-11-04 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
Responder patients were defined as those subjects showing an improvement of at least 15% in the ALSFRS-R slope during the treatment period as compared to the lead-in period. (NCT00877604)
Timeframe: 1 year
| Intervention | participants (Number) |
|---|---|
| TUDCA | 13 |
| Placebo | 6 |
2 reviews available for 3-hydroxybutyric acid and Parkinson Disease
| Article | Year |
|---|---|
Beneficial Effects of Exogenous Ketogenic Supplements on Aging Processes and Age-Related Neurodegenerative Diseases.
Topics: 3-Hydroxybutyric Acid; Aging; Alzheimer Disease; Diet, Ketogenic; Dietary Supplements; Epigenomics; | 2021 |
Ketogenic diet in neuromuscular and neurodegenerative diseases.
Topics: 3-Hydroxybutyric Acid; Alzheimer Disease; Amyotrophic Lateral Sclerosis; Brain; Diet, Ketogenic; Glu | 2014 |
Ketogenic diet in neuromuscular and neurodegenerative diseases.
Topics: 3-Hydroxybutyric Acid; Alzheimer Disease; Amyotrophic Lateral Sclerosis; Brain; Diet, Ketogenic; Glu | 2014 |
Ketogenic diet in neuromuscular and neurodegenerative diseases.
Topics: 3-Hydroxybutyric Acid; Alzheimer Disease; Amyotrophic Lateral Sclerosis; Brain; Diet, Ketogenic; Glu | 2014 |
Ketogenic diet in neuromuscular and neurodegenerative diseases.
Topics: 3-Hydroxybutyric Acid; Alzheimer Disease; Amyotrophic Lateral Sclerosis; Brain; Diet, Ketogenic; Glu | 2014 |
Ketogenic diet in neuromuscular and neurodegenerative diseases.
Topics: 3-Hydroxybutyric Acid; Alzheimer Disease; Amyotrophic Lateral Sclerosis; Brain; Diet, Ketogenic; Glu | 2014 |
Ketogenic diet in neuromuscular and neurodegenerative diseases.
Topics: 3-Hydroxybutyric Acid; Alzheimer Disease; Amyotrophic Lateral Sclerosis; Brain; Diet, Ketogenic; Glu | 2014 |
Ketogenic diet in neuromuscular and neurodegenerative diseases.
Topics: 3-Hydroxybutyric Acid; Alzheimer Disease; Amyotrophic Lateral Sclerosis; Brain; Diet, Ketogenic; Glu | 2014 |
Ketogenic diet in neuromuscular and neurodegenerative diseases.
Topics: 3-Hydroxybutyric Acid; Alzheimer Disease; Amyotrophic Lateral Sclerosis; Brain; Diet, Ketogenic; Glu | 2014 |
Ketogenic diet in neuromuscular and neurodegenerative diseases.
Topics: 3-Hydroxybutyric Acid; Alzheimer Disease; Amyotrophic Lateral Sclerosis; Brain; Diet, Ketogenic; Glu | 2014 |
Ketogenic diet in neuromuscular and neurodegenerative diseases.
Topics: 3-Hydroxybutyric Acid; Alzheimer Disease; Amyotrophic Lateral Sclerosis; Brain; Diet, Ketogenic; Glu | 2014 |
Ketogenic diet in neuromuscular and neurodegenerative diseases.
Topics: 3-Hydroxybutyric Acid; Alzheimer Disease; Amyotrophic Lateral Sclerosis; Brain; Diet, Ketogenic; Glu | 2014 |
Ketogenic diet in neuromuscular and neurodegenerative diseases.
Topics: 3-Hydroxybutyric Acid; Alzheimer Disease; Amyotrophic Lateral Sclerosis; Brain; Diet, Ketogenic; Glu | 2014 |
Ketogenic diet in neuromuscular and neurodegenerative diseases.
Topics: 3-Hydroxybutyric Acid; Alzheimer Disease; Amyotrophic Lateral Sclerosis; Brain; Diet, Ketogenic; Glu | 2014 |
Ketogenic diet in neuromuscular and neurodegenerative diseases.
Topics: 3-Hydroxybutyric Acid; Alzheimer Disease; Amyotrophic Lateral Sclerosis; Brain; Diet, Ketogenic; Glu | 2014 |
Ketogenic diet in neuromuscular and neurodegenerative diseases.
Topics: 3-Hydroxybutyric Acid; Alzheimer Disease; Amyotrophic Lateral Sclerosis; Brain; Diet, Ketogenic; Glu | 2014 |
Ketogenic diet in neuromuscular and neurodegenerative diseases.
Topics: 3-Hydroxybutyric Acid; Alzheimer Disease; Amyotrophic Lateral Sclerosis; Brain; Diet, Ketogenic; Glu | 2014 |
1 trial available for 3-hydroxybutyric acid and Parkinson Disease
| Article | Year |
|---|---|
Treatment of Parkinson disease with diet-induced hyperketonemia: a feasibility study.
Topics: 3-Hydroxybutyric Acid; Acetoacetates; Aged; Antiparkinson Agents; Cholesterol; Combined Modality The | 2005 |
Treatment of Parkinson disease with diet-induced hyperketonemia: a feasibility study.
Topics: 3-Hydroxybutyric Acid; Acetoacetates; Aged; Antiparkinson Agents; Cholesterol; Combined Modality The | 2005 |
Treatment of Parkinson disease with diet-induced hyperketonemia: a feasibility study.
Topics: 3-Hydroxybutyric Acid; Acetoacetates; Aged; Antiparkinson Agents; Cholesterol; Combined Modality The | 2005 |
Treatment of Parkinson disease with diet-induced hyperketonemia: a feasibility study.
Topics: 3-Hydroxybutyric Acid; Acetoacetates; Aged; Antiparkinson Agents; Cholesterol; Combined Modality The | 2005 |
8 other studies available for 3-hydroxybutyric acid and Parkinson Disease
| Article | Year |
|---|---|
β-Hydroxybutyrate alleviates pyroptosis in MPP
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; 1-Methyl-4-phenylpyridinium; 3-Hydroxybutyric Acid; An | 2022 |
β-Hydroxybutyrate alleviates pyroptosis in MPP
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; 1-Methyl-4-phenylpyridinium; 3-Hydroxybutyric Acid; An | 2022 |
β-Hydroxybutyrate alleviates pyroptosis in MPP
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; 1-Methyl-4-phenylpyridinium; 3-Hydroxybutyric Acid; An | 2022 |
β-Hydroxybutyrate alleviates pyroptosis in MPP
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; 1-Methyl-4-phenylpyridinium; 3-Hydroxybutyric Acid; An | 2022 |
β-Hydroxybutyrate alleviates pyroptosis in MPP
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; 1-Methyl-4-phenylpyridinium; 3-Hydroxybutyric Acid; An | 2022 |
β-Hydroxybutyrate alleviates pyroptosis in MPP
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; 1-Methyl-4-phenylpyridinium; 3-Hydroxybutyric Acid; An | 2022 |
β-Hydroxybutyrate alleviates pyroptosis in MPP
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; 1-Methyl-4-phenylpyridinium; 3-Hydroxybutyric Acid; An | 2022 |
β-Hydroxybutyrate alleviates pyroptosis in MPP
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; 1-Methyl-4-phenylpyridinium; 3-Hydroxybutyric Acid; An | 2022 |
β-Hydroxybutyrate alleviates pyroptosis in MPP
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; 1-Methyl-4-phenylpyridinium; 3-Hydroxybutyric Acid; An | 2022 |
Increased Beta-Hydroxybutyrate Level Is Not Sufficient for the Neuroprotective Effect of Long-Term Ketogenic Diet in an Animal Model of Early Parkinson's Disease. Exploration of Brain and Liver Energy Metabolism Markers.
Topics: 3-Hydroxybutyric Acid; Animals; Brain; Diet, Ketogenic; Disease Models, Animal; Dopaminergic Neurons | 2021 |
The Ketone Body β-Hydroxybutyrate Does Not Inhibit Synuclein Mediated Inflammasome Activation in Microglia.
Topics: 3-Hydroxybutyric Acid; Animals; Humans; Inflammasomes; Mice; Microglia; Parkinson Disease; Synuclein | 2017 |
Anti-inflammatory effects of BHBA in both in vivo and in vitro Parkinson's disease models are mediated by GPR109A-dependent mechanisms.
Topics: 3-Hydroxybutyric Acid; Animals; Anti-Inflammatory Agents; Calcium-Binding Proteins; Cells, Cultured; | 2015 |
Nitrosative stress mediated misfolded protein aggregation mitigated by Na-D-β-hydroxybutyrate intervention.
Topics: 3-Hydroxybutyric Acid; Apoptosis; Carrier Proteins; Caspases; Cell Line, Tumor; Dopaminergic Neurons | 2012 |
D-beta-hydroxybutyrate rescues mitochondrial respiration and mitigates features of Parkinson disease.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; 3-Hydroxybutyric Acid; Adenosine Triphosphate; Animals | 2003 |
Similar patterns of mitochondrial vulnerability and rescue induced by genetic modification of alpha-synuclein, parkin, and DJ-1 in Caenorhabditis elegans.
Topics: 3-Hydroxybutyric Acid; alpha-Synuclein; Amino Acid Sequence; Animals; Animals, Genetically Modified; | 2005 |
D-beta-hydroxybutyrate protects neurons in models of Alzheimer's and Parkinson's disease.
Topics: 1-Methyl-4-phenylpyridinium; 3-Hydroxybutyric Acid; Alzheimer Disease; Amyloid beta-Peptides; Animal | 2000 |